Literature DB >> 9156279

Molecular and cellular biology of prostate cancer.

M E Laniado, P D Abel.   

Abstract

Prostate cancer is an enigmatic disease. Although prostatic-intraepithelial neoplasia appears as early as the third decade and as many as 80% of 80 year old men have epithelial cells in their prostate that fit the morphological criteria for cancer, only about 10% of men will ever have the clinical disease and less than 3% will die from it. There have been no significant proven interventions which have altered the natural history of the disease since hormone down regulation was introduced in the 1940s and new research has been poorly supported. There is however an urgent need to develop new criteria to distinguish those patients with localised disease who will benefit from intervention from those that do not require it or who will have occult extra prostatic metastases. Similarly, there is an urgent need to develop new treatments for those in whom the disease is extra-prostatic and therefore incurable by conventional treatments. This review covers the latest developments in epidemiology, cellular and molecular biology including new areas such as ion channels in the field of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156279     DOI: 10.1023/a:1005792206377

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  13 in total

1.  Differential experimental micrometastasis to lung, liver, and bone with lacZ-tagged CWR22R prostate carcinoma cells.

Authors:  Julianne L Holleran; Carson J Miller; Nancy L Edgehouse; Theresa P Pretlow; Lloyd A Culp
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 2.  Molecular chaperones in the etiology and therapy of cancer.

Authors:  C Soti; P Csermely
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.

Authors:  R S Hubert; I Vivanco; E Chen; S Rastegar; K Leong; S C Mitchell; R Madraswala; Y Zhou; J Kuo; A B Raitano; A Jakobovits; D C Saffran; D E Afar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

5.  Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.

Authors:  D C Saffran; A B Raitano; R S Hubert; O N Witte; R E Reiter; A Jakobovits
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

6.  Analysis of protooncogene c-erbB-2 in benign and malignant human prostate.

Authors:  M Watanabe; T Nakada; H Yuta
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 7.  Molecular pathology of prostate cancer.

Authors:  C Hughes; A Murphy; C Martin; O Sheils; J O'Leary
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

8.  Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.

Authors:  Joanna Nightingale; Khurram S Chaudhary; Paul D Abel; Andrew P Stubbs; Hanna M Romanska; Stephen E Mitchell; Gordon W H Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

9.  A role for STEAP2 in prostate cancer progression.

Authors:  Helen Whiteland; Samantha Spencer-Harty; Claire Morgan; Howard Kynaston; David Hywel Thomas; Pradeep Bose; Neil Fenn; Paul Lewis; Spencer Jenkins; Shareen H Doak
Journal:  Clin Exp Metastasis       Date:  2014-09-24       Impact factor: 5.150

Review 10.  Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.